Heart 2001;85:544-548 ( May )

Cardiovascular medicine

An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia P N Durrington, D Bhatnagar, M I Mackness, J Morgan, K Julier, M A Khan, M France

University Department of Medicine, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WL, UK

Correspondence to: Professor Durrington pdurrington{at}hq.cmht.nwest.nhs.uk

Accepted 12 September 2000

BACKGROUNDOmega-3 fatty acids, such as those present in fish oil, have been reported to prolong life in myocardial infarction survivors. These fatty acids can decrease serum triglyceride concentrations, but so far the doses used in trials examining their effects on coronary end points have had only minimal triglyceride lowering effects.
OBJECTIVETo examine the triglyceride lowering effectiveness, safety, and tolerability of Omacor, a concentrate of omega-3, long chain, polyunsaturated fatty acids from fish oil (84% of the total as opposed to an average of 35% in fish oil) over one year in patients with established coronary heart disease (CHD) and persisting hypertriglyceridaemia, despite receiving simvastatin in doses similar to those employed in the Scandinavian simvastatin survival study.
SUBJECTS AND METHODS59 patients with CHD, receiving simvastatin 10-40 mg daily with serum triglycerides > 2.3 mmol/l, were randomised to receive Omacor 2 g twice a day or placebo for 24 weeks in a double blind trial. Forty six patients accepted the offer of active treatment for a further 24 weeks in an open phase of the trial.
RESULTSThere was a sustained significant decrease in serum triglycerides by 20-30% (p < 0.005) and in very low density lipoprotein (VLDL) cholesterol by 30-40% (p < 0.005) in patients receiving active Omacor at three, six, and 12 months compared either to baseline or placebo. Omacor did not have any deleterious effect on low density or high density lipoprotein cholesterol or on biochemical and haematological safety tests. There was no adverse effect on glycaemic control in patients with diabetes, who showed a decrease in serum triglyceride, which was at least as great as in non-diabetic patients. One patient receiving placebo died of acute myocardial infarction. Three patients withdrew from the trial (two on placebo and one on active treatment). Omacor was generally well tolerated.
CONCLUSIONOmacor was found to be a safe and effective means of lowering serum triglycerides over one year in patients with CHD and combined hyperlipidaemia, whose triglycerides remained elevated despite simvastatin treatment.


Keywords: coronary heart disease; hypertriglyceridaemia; polyunsaturated fat; statin treatment

---

© 2001 by Heart
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Sharma, M., Ansari, M. T., Abou-Setta, A. M., Soares-Weiser, K., Ooi, T. C., Sears, M., Yazdi, F., Tsertsvadze, A., Moher, D. (2009). Systematic Review: Comparative Effectiveness and Harms of Combination Therapy and Monotherapy for Dyslipidemia. ANN INTERN MED 151: 622-630 [Abstract] [Full Text]  
• Bitzur, R., Cohen, H., Kamari, Y., Shaish, A., Harats, D. (2009). Triglycerides and HDL Cholesterol: Stars or second leads in diabetes?. Diabetes Care 32: S373-S377 [Full Text]  
• Potenza, M. V., Mechanick, J. I. (2009). The Metabolic Syndrome: Definition, Global Impact, and Pathophysiology. Nutr Clin Pract 24: 560-577 [Abstract] [Full Text]  
• Sharma, M., Ansari, M. T., Abou-Setta, A. M., Soares-Weiser, K., Ooi, T. C., Sears, M., Yazdi, F., Tsertsvadze, A., Moher, D. (2009). Systematic Review: Comparative Effectiveness and Harms of Combinations of Lipid-Modifying Agents and High-Dose Statin Monotherapy. ANN INTERN MED 0: 0000605-200911030-00144v1-E-144 [Abstract] [Full Text]  
• Cornier, M.-A., Dabelea, D., Hernandez, T. L., Lindstrom, R. C., Steig, A. J., Stob, N. R., Van Pelt, R. E., Wang, H., Eckel, R. H. (2008). The Metabolic Syndrome. Endocr. Rev. 29: 777-822 [Abstract] [Full Text]  
• Jacobson, T. A (2008). Role of n-3 fatty acids in the treatment of hypertriglyceridemia and cardiovascular disease. Am. J. Clin. Nutr. 87: 1981S-1990S [Abstract] [Full Text]  
• Feagan, B. G., Sandborn, W. J., Mittmann, U., Bar-Meir, S., D'Haens, G., Bradette, M., Cohen, A., Dallaire, C., Ponich, T. P., McDonald, J. W. D., Hebuterne, X., Pare, P., Klvana, P., Niv, Y., Ardizzone, S., Alexeeva, O., Rostom, A., Kiudelis, G., Spleiss, J., Gilgen, D., Vandervoort, M. K., Wong, C. J., Zou, G. Y., Donner, A., Rutgeerts, P. (2008). Omega-3 Free Fatty Acids for the Maintenance of Remission in Crohn Disease: The EPIC Randomized Controlled Trials. JAMA 299: 1690-1697 [Abstract] [Full Text]  
• McKenney, J. M., Sica, D. (2007). Prescription omega-3 fatty acids for the treatment of hypertriglyceridemia. Am J Health Syst Pharm 64: 595-605 [Abstract] [Full Text]  
• Schwellenbach, L. J., Olson, K. L., McConnell, K. J., Stolcpart, R. S., Nash, J. D., Merenich, J. A., for the Clinical Pharmacy Cardiac Risk Service Stu, (2006). The Triglyceride-Lowering Effects of a Modest Dose of Docosahexaenoic Acid Alone Versus in Combination with Low Dose Eicosapentaenoic Acid in Patients with Coronary Artery Disease and Elevated Triglycerides. J. Am. Coll. Nutr. 25: 480-485 [Abstract] [Full Text]  
• Nies, L. K, Cymbala, A. A, Kasten, S. L, Lamprecht, D. G, Olson, K. L (2006). Complementary and Alternative Therapies for the Management of Dyslipidemia. The Annals of Pharmacotherapy 40: 1984-1992 [Abstract] [Full Text]  
• Oh, R. (2005). Practical Applications of Fish Oil ({Omega}-3 Fatty Acids) in Primary Care. J Am Board Fam Med 18: 28-36 [Abstract] [Full Text]  
• Durrington, P. (2003). Clinical trials of lipid-lowering medication in diabetes. British Journal of Diabetes & Vascular Disease 3: 217-220 [Abstract]